Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388638 | 0.88 | RAB9A (0.36) | TAAR1LTB4RLTB4R2RAB9AKMT2A | |
| SCHEMBL5388716 | 0.85 | KMT2A (0.43) | TAAR1LTB4RLTB4R2RAB9AKMT2A | |
| SCHEMBL5396925 | 0.81 | BDKRB1 (0.36) | MAPTALDH1A1 | |
| SCHEMBL5393153 | 0.79 | LTB4R (0.42) | LTB4RLTB4R2KMT2AMEN1MAPT | |
| SCHEMBL5378824 | 0.77 | MEN1 (0.41) | TAAR1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5457826 | 0.77 | NR1H2 (0.38) | LTB4RLTB4R2ALDH1A1NPC1 | |
| SCHEMBL5393160 | 0.76 | CA1 (0.39) | TAAR1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL5388785 | 0.75 | NR1H2 (0.35) | RAB9A | |
| SCHEMBL5393881 | 0.74 | KMT2A (0.38) | LTB4RLTB4R2RAB9AKMT2AMEN1 | |
| SCHEMBL5396927 | 0.74 | BDKRB1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | TAAR1 189/4885SLC6A4 2316/4885LTB4R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.